W Eisterer
Reply to the letter to the editor "Anti-EGFR therapy in oesophagogastric cancer: precise but not enough" by M. Salati and S. Cascinu
Ruhstaller T, Langer R, Thuss-Patience P, Eisterer W, Stahl M. Reply to the letter to the editor "Anti-EGFR therapy in oesophagogastric cancer: precise but not enough" by M. Salati and S. Cascinu. Ann Oncol 2018
09.07.2018Reply to the letter to the editor "Anti-EGFR therapy in oesophagogastric cancer: precise but not enough" by M. Salati and S. Cascinu
09.07.2018Ann Oncol 2018
Ruhstaller Thomas, Langer R, Thuss-Patience P, Eisterer W, Stahl M
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
Ruhstaller T, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol 2018; 29:1386-1393.
01.06.2018Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
01.06.2018Ann Oncol 2018; 29:1386-1393
Ruhstaller Thomas, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S C, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J R, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch
Effect of cyclosporin A in a patient with refractory nephrotic syndrome associated with B chronic lymphocytic leukemia
Eisterer W, Neyer U, Hilbe W, Diem G, Öhlschlegel C, Ludescher C, Thaler J. Effect of cyclosporin A in a patient with refractory nephrotic syndrome associated with B chronic lymphocytic leukemia. Nephron 1996; 72:468-71.
01.01.1996Effect of cyclosporin A in a patient with refractory nephrotic syndrome associated with B chronic lymphocytic leukemia
01.01.1996Nephron 1996; 72:468-71
Eisterer W, Neyer U, Hilbe W, Diem G, Öhlschlegel Christian, Ludescher C, Thaler J